Eli Lilly continues to back a potential COVID-19 treatment despite research showing that it may not work on hospitalized patients.

Lilly expects full-year earnings in the range of $7.20 to $7.40 per share, with revenue in the range of $23.7 billion to $24.2 billion. That's short of the per-share earnings that Wall Street was looking for

Eli Lilly paused trials of its COVID-19 treatment drug Tuesday. The news came less than a day after Johnson & Johnson also paused its trial on a COVID-19 vaccine.

Indianapolis-based Eli Lilly has requested emergency use authorization, from the Food and Drug Administration, for its COVID-19 single antibody treatment.

Indianapolis-based Eli Lilly and Company says it has asked the U.S. government to allow emergency use of an experimental antibody therapy based on early results from a study.

Indianapolis-based Eli Lilly announced Wednesday its COVID-19 antibody drug is showing results in reducing hospitalizations from the virus. This is the companys first data to be reported on mild to moderate cases but still needs to be reviewed by peers.

Eli Lilly says that partial results from a study testing an antibody drug give hints that it may help mild to moderately ill COVID-19 patients from needing to be hospitalized, a goal no current coronavirus medicine has been able to meet.

Eli Lilly announced the results Monday from a 1,000-person study sponsored by the U.S. National Institute of Allergy and Infectious Diseases. The result have not yet been published or reviewed by independent scientists.

Indianapolis-based Eli Lilly is moving to Phase 3 testing of a treatment to prevent COVID-19 after initial success. The next step will be to test the drug at nursing homes where the pandemic has hit hard.

Lilly Foundation's financial commitment over five years is aimed at finding solutions to racial inequity and social injustice primarily in Indianapolis, its surrounding counties and nationally.